Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease
Open Access
- 30 June 2013
- journal article
- Published by Elsevier BV in Neurobiology of Aging
- Vol. 34 (6), 1712.e9-1712.e13
- https://doi.org/10.1016/j.neurobiolaging.2012.12.020
Abstract
No abstract availableKeywords
Funding Information
- Telethon (GTB07001)
- “Fondazione Grigioni per il Morbo di Parkinson.”
This publication has 26 references indexed in Scilit:
- Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcomePsychiatric Genetics, 2008
- Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's diseaseAnnals of Neurology, 2008
- Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal NeurodegenerationJournal of Neuroscience, 2007
- Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson DiseaseJournal of Cerebral Blood Flow & Metabolism, 2006
- Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in womenHuman Molecular Genetics, 2005
- Association of DNA Polymorphisms in the Synaptic Vesicular Amine Transporter Gene (SLC18A2) with Alcohol and Nicotine DependenceNeuropsychopharmacology, 2005
- SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholismHuman Molecular Genetics, 2005
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Score Tests for Association between Traits and Haplotypes when Linkage Phase Is AmbiguousAmerican Journal of Human Genetics, 2002
- Molecular cloning and characterization of a human DNA binding factor that represses transcriptionCell, 1989